I think the point about mitochondrial dysfunction is that it is like a car crashing. It does not really matter how many different examples people study of what happens when a car crashes such as into a wall, a river, a sea, a nuclear power station or a tree (etc), what people are not studying is what causes the car to crash.
1 Like
Preprint α-Synuclein (α-Syn) accumulation is a central pathological feature of Parkinson’s disease, yet its impact extends beyond proteostasis failure. Here, we identify intracellular pH dysregulation as a previously unrecognized consequence of α-Syn overexpression in neuronally differentiated SH-SY5Y cells. α-Syn promotes cytosolic acidification by stabilizing the acid-loading anion exchanger AE2 (SLC4A2) through mTOR-dependent impairment of lysosomal degradation. Pharmacological modulation of this pathway revealed opposite effects on AE2 turnover: rapamycin rescued, whereas bafilomycin A1 exacerbated, AE2 accumulation, in parallel with reciprocal changes in intracellular pH (alkalinization with rapamycin and further acidification with bafilomycin). Because acidic conditions favor misfolding and aggregation of this intrinsically disordered protein, α-Syn–driven acidification may establish a self-reinforcing pathogenic loop that fuels disease progression. Our findings identify AE2-mediated acid loading as a central driver of α-Syn–induced cellular dysfunction, establishing intracellular pH dysregulation as a possible core pathogenic mechanism in synucleinopathies.
The rescue achieved by rapamycin-mediated mTORC1 inhibition is particularly informative in this context. The preferential recovery of pHi observed in SNCA cells after rapamycin treatment indicates that mTOR hyperactivation is the primary signal maintaining lysosomal dysfunction. This is consistent with reports that pathological α-synuclein disrupts the TSC1–TSC2 complex to sustain mTORC1 activity and with the broader literature linking mTOR dysregulation to impaired lysosomal biogenesis and autophagic clearance in patient tissues (8–10). Restoration of AE2 turnover following mTORC1 inhibition further supports the conclusion that reactivation of autophagic flux is sufficient to normalize intracellular acid balance.
Macroautophagy activator rapamycin reversed (G603R) Lrp10-induced increment of α-synuclein, death of SN dopaminergic cells and PD locomotor disability in Lrp10G603R/+ mouse.
That is after the car crashed into the tree and the tree fell over damaging a house.
And rapamycin doesn’t cross the BBB, so… of course, this is mice, but the other paper (“rapamycin rescues”) poses the same question. If this is down to mTORC1, I wish they would look at everolimus effect on alpha-syn and dopa cells compared to sirolimus.
On a different note I was looking at alpha-syn and prodromal PD, and wondering what were the differences between early onset vs late onset PD. Frustratingly, I cannot find much - most is in 60+
Neuronally Derived Extracellular Vesicle α-Synuclein as a Serum Biomarker for Individuals at Risk of Developing Parkinson Disease
https://jamanetwork.com/journals/jamaneurology/fullarticle/2812433
“A number of nonmotor symptoms, such as rapid eye movement sleep behavior disorder (RBD), olfactory loss, or autonomic dysfunction can manifest during the prodromal phase and are associated with higher risk of phenoconversion to PD.[1]Isolated RBD (iRBD) is the strongest predictor of α-synucleinopathy with more than 80% of participants converting to PD, dementia with Lewy bodies (DLB), or multiple system atrophy (MSA) within 12 years.[2]”
2 Likes
If PD is the failure of dopaminergic neurons then prodomal PD is where they are failing a bit and the full blown disease is when they are failing badly.
I would argue that the subtleties between the symptoms of these do not give us that much information as to the cause (which I believe to be a failure of the mitochondrial homeostasis much like accelerated aging).
1 Like
Anyone looked into capsaicin for Parkinson’s? According to the following studies:
Capsaicin increases the number of dopaminergic neurons and the expression of the enzyme tyrosine hydroxylase (TH) in those neurons.
Increasing TH expression will increase the dopamine output despite reduced surviving neurons.
This in combination with the supposed increase in dopaminergic neurons which is quite miraculous this should be an effective treatment. I do have my doubts on how effective this would be but I think it would be a useful ancillary supplement for anyone with any condition of dopaminergic insufficiency. Though this study only confirms the increase in dopaminergic neuron amount and TH expression in the substantia nigra segment of the brain.
It also had impressive anti-inflammatory effects where it reduced certain ROS and key cytokines including TNF-α, IL-1β, IL-6.
It also seemed to increase glutathione production in the brain but this was in a cell culture not in an animal or human study.
Another study showed it reduced beta amyloid plaque production. There was an association between higher spicy food consumption and higher cognitive ability + lower beta amyloid plaque levels.
But then a follow up study that went on for 15 years that addressed the claims of the previous study showing the association of higher spicy food consumption and higher cognitive ability actually showed the opposite. So perhaps moderate chili intake is the answer.
“The main symptoms of Parkinson’s disease are tremor, rigidity, and bradykinesia, all of which are caused by the degeneration of tyrosine hydroxylase positive dopaminergic neurons in the substantia nigra. Consequently, there is less dopamine in the striatum because substantia nigra neurons project to the striatum. MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and its active metabolite MPP+ (1-methyl-4-phenylpyridinium), are toxic chemical compounds that cause neurodegeneration of substantia nigra neurons. Therefore, MPTP and MPP+ treated animals are used as models of Parkinson’s disease [31,32].
Different interconnected mechanisms cause substantia nigra neurodegeneration in Parkinson’s disease, for example, alpha-synuclein aggregation, mitochondrial dysfunction, and microglial activation [31,32]. It was found that activated microglia contribute to the neurodegeneration process in the substantia nigra by producing oxidants and proinflammatory cytokines [31].
It was repeatedly found that capsaicin reduced neurodegeneration and motor impairment in animal models of Parkinson’s disease [12,31,33,34,35,36]. This compound exerted beneficial effects on Parkinson’s disease by decreasing microglial activation and reducing neuroinflammation [12,31,35,37]. These findings are summarized in Figure 3.
The beneficial effects of capsaicin in Parkinson’s disease are shown in simplified form. Capsaicin administration increases the number of dopaminergic neurons in the substantia nigra and the expression of tyrosine hydroxylase in these neurons. Consequently, there is more dopamine in the striatum. Moreover, after capsaicin treatment, microglial cells in the substantia nigra produce fewer oxidants and inflammatory cytokines. Left panel—before capsaicin treatment, right panel—after capsaicin treatment.
In an MPTP mouse model of Parkinson’s disease, it was found that intraperitoneal application of capsaicin (0.5 mg/kg) increased the number of dopaminergic (tyrosine hydroxylase positive) neurons in the substantia nigra. This effect was dependent on TRPV1 channels. The authors also found that capsaicin improved motor impairment and suggested that one of the mechanisms of these beneficial effects was that this compound decreased the production of reactive oxygen species and proinflammatory cytokines (TNF-α and IL-β) by activated microglia [31]. Similar results were obtained by a different laboratory in a lipopolysaccharide rat model of Parkinson’s disease. The authors found that intraperitoneal capsaicin (1 mg/kg) reduced neurodegeneration in the substantia nigra. In the presence of the tested compound, microglial cells shifted from a proinflammatory to an anti-inflammatory state and produced fewer oxidants and proinflammatory cytokines (IL-1β and IL-6). These neuroprotective effects were dependent on TRPV1 channels because they were reduced after administration of a selective TRPV1 inhibitor, capsazepine [35].
Not only microglial cells but also astrocytes (a different type of glial cell) are influenced by capsaicin in Parkinson’s disease [36]. It was found in an MPP+ animal model that capsaicin applied intraperitoneally (1 mg/kg; a single injection/day for 7 days) activated TRPV1 receptors on astrocytes in the substantia nigra. TRPV1 receptors activation enhanced the production of a ciliary neurotrophic factor by astrocytes which increased tyrosine hydroxylase activity in the substantia nigra and dopamine levels in the striatum [36]. Capsaicin also caused behavioral recovery in MPP+ animals. In a different study from the same laboratory, it was found in the same model of Parkinson’s disease that activated microglia produced fewer reactive oxygen species in the substantia nigra after intraperitoneal administration of capsaicin (1 mg/kg). Microglia-derived oxidative stress was reduced by a ciliary neurotrophic factor produced by capsaicin-stimulated astrocytes in the substantia nigra [12]. This effect of capsaicin reduced neurodegeneration and decreased motor impairment in MPP+ rats.
Alpha-synuclein deposition is an important feature of Parkinson’s disease [32]. A protective role of dietary capsaicin (20, 40, 80 and 100 μM for 24 days) against Parkinson’s disease was reported in flies expressing human alpha-synuclein. It was found that capsaicin increased dopamine content, reduced oxidative stress markers, and enhanced free radical scavenging potential in brains obtained from flies with Parkinson’s disease [38].
To summarize, capsaicin treatment reduces neurodegeneration and improves behavioral outcomes in different animal models of Parkinson’s disease. The important mechanism of this effect is that this compound reduces oxidants and proinflammatory cytokines production by activated microglia. This process is shown schematically in Figure 3.” - Beneficial Effects of Capsaicin in Disorders of the Central Nervous System Beneficial Effects of Capsaicin in Disorders of the Central Nervous System - PMC
“The present study aimed to identify the gene expression changes conferred by capsaicin in the cell model of 6-OHDA-induced Parkinson’s disease, to disclose the molecular mechanism of action of capsaicin. We used capsaicin-treated and paraffin-embedded wax blocks containing substantia nigra tissue from 6-OHDA-induced Parkinson’s disease rats to analyze transcriptional changes using Affymetrix GeneChip Whole Transcript Expression Arrays. A total of 108 genes were differentially expressed in response to capsaicin treatment, and seven of these genes were selected for further analysis: Olr724, COX1, Gsta2, Rab5a, Potef, Actg1, and Acadsb, of which Actg1 (actin gamma 1) was down-regulated and Gsta2 (Glutathione S-transferase alpha 2) was up-regulated. We successfully overexpressed Actg1 and Gsta2 in vitro. CCK-8 detection and flow cytometry demonstrated that overexpression of Actg1 and Gsta2 increased apoptosis in the 6-OHDA-induced Parkinson’s disease cell model. The imbalance between Actg1 and Gsta2 may be one of the mechanisms of cell damage in Parkinson’s disease (PD). Capsaicin can protect the cells and reduce the apoptosis rate by regulating Actg1 and Gsta2.” - Regulation of Actg1 and Gsta2 is possible mechanism by which capsaicin alleviates apoptosis in cell model of 6-OHDA-induced Parkinson’s disease https://portlandpress.com/bioscirep/article/40/6/BSR20191796/225257/Regulation-of-Actg1-and-Gsta2-is-possible
“Previous studies suggest that there is a geographic overlap between AD incidence and spicy food consumption. We previously reported that capsaicin-rich diet consumption was associated with better cognition and lower serum Amyloid-beta (Aβ) levels in people aged 40 years and over. In the present study, we found that intake of capsaicin, the pungent ingredient in chili peppers, reduced brain Aβ burden and rescued cognitive decline in APP/PS1 mice. Our in vivo and in vitro studies revealed that capsaicin shifted Amyloid precursor protein (APP) processing towards α-cleavage and precluded Aβ generation by promoting the maturation of a disintegrin and metalloproteinase 10 (ADAM10). We also found that capsaicin alleviated other AD-type pathologies, such as tau hyperphosphorylation, neuroinflammation and neurodegeneration. The present study suggests that capsaicin is a potential therapeutic candidate for AD and warrants clinical trials on chili peppers or capsaicin as dietary supplementation for the prevention and treatment of AD.” - Capsaicin consumption reduces brain amyloid-beta generation and attenuates Alzheimer’s disease-type pathology and cognitive deficits in APP/PS1 mice Capsaicin consumption reduces brain amyloid-beta generation and attenuates Alzheimer’s disease-type pathology and cognitive deficits in APP/PS1 mice - PMC
“We aimed to examine the association between chili intake and cognitive function in Chinese adults. This is a longitudinal study of 4852 adults (age 63.4 ± 7.7) attending the China Health and Nutrition Survey during 1991 and 2006. Cognitive function was assessed in 1997, 2000, 2004 and 2006. In total, 3302 completed cognitive screening tests in at least two surveys. Chili intake was assessed by a 3-day food record during home visits in each survey between 1991 and 2006. Multivariable mixed linear regression and logistic regression were used. Chili intake was inversely related to cognitive function. In fully adjusted models, including sociodemographic and lifestyle factors, compared with non-consumers, those whose cumulative average chili intake above 50 g/day had the regression coefficients (and 95% CI) for global cognitive function of −1.13 (−1.71–0.54). Compared with non-consumers, those with chili consumption above 50 g/day had the odds ratio (and 95% CI) of 2.12(1.63–2.77), 1.56(1.23–1.97) for self-reported poor memory and self-reported memory decline, respectively. The positive association between chili intake and cognitive decline was stronger among those with low BMI than those with high BMI. The longitudinal data indicate that higher chili intake is positively associated with cognitive decline in Chinese adults in both genders.” - High Chili Intake and Cognitive Function among 4582 Adults: An Open Cohort Study over 15 Years https://www.researchgate.net/publication/333413321_High_Chili_Intake_and_Cognitive_Function_among_4582_Adults_An_Open_Cohort_Study_over_15_Years
2 Likes
Preprint CUHK: Neuroprotective Effect of Melatonin in Isolated Rapid Eye Movement Sleep Behavior Disorder
Methods: This longitudinal cohort study included 194 video-polysomnography-confirmed patients with iRBD from a single center in Hong Kong from 2007 to 2023, with a median follow-up of 5·5 years. The primary exposure of interest was the continued use of melatonin as per prescription records versus discontinued use. The primary outcome was phenoconversion risk to PD or DLB. Secondary outcomes included longitudinal changes in neurodegenerative signs/biomarkers using generalized linear mixed-effects models. Melatonin exposure was further handled as a time-varying covariate in survival analyses, and the minimal effective dosage was estimated via penalized splines.
Findings: Among 194 patients (mean [SD] age, 66·2 [7·3] years; 140 [72·2%] male), continued melatonin use was associated with a significantly lower risk of phenoconversion (adjusted hazard ratio [aHR], 0·47; 95% CI, 0·26-0·83), particularly for DLB (aHR, 0·28; 95% CI, 0·10-0·76). This association persisted after propensity score matching and weighting. As a time-varying covariate, melatonin showed a dose-dependent protective effect (aHR, 0·91; 95% CI, 0·85-0·99 for any phenoconversion; aHR, 0·88; 95% CI, 0·79-0·99 for DLB), with an estimated minimal effective dose of 7·0 mg. Continued melatonin use was also associated with slower declines in RBD symptom severity, global cognition, color vision, visuospatial/attentional function, and motor coordination.
Interpretation: Continued melatonin use was associated with a reduced risk of phenoconversion to overt α-synucleinopathies in patients with iRBD, suggesting a potential neuroprotective effect in this high-risk population.
Beyond its well-established symptomatic efficacy and favorable safety profile, melatonin may serve as a feasible, low-risk neuroprotective strategy for individuals in the prodromal stage of neurodegeneration.
This HK team somehow replicates previous German findings: Parkinson's disease - #679 by adssx
@John_Hemming vindicated once again? Poke @CronosTempi you might want to increase your melatonin dose?
2 Likes
Thank you. The question that needs answering is whether a high enough dose of melatonin enables the normal range of mitophagy to increase ⟨ΔΨm⟩
By the way, there are those ongoing trials:
- Disease Modifying Potential of 5mg of Melatonin on Cognition and Brain Health in Aging, NCT03954899
- Effect of Melatonin on Oxidative Stress Parameters in Levodopa-Treated Parkinson’s Disease Patients, NCT07375693
- Effects of 3-Month Melatonin Treatment on Regional Cerebellar Structure and Blood Biomarkers in Alzheimer’s Disease Spectrum, NCT06756828
These are 5, 10 and 2 mg of melatonin. I think the mistake made by people in looking at dosing is that they don’t take into account the fact that a lot of melatonin (ordinarily) is injected directly into the CSF by the pineal. Hence the brain has much higher concentrations than the serum peak.
Hence I think these doses are really quite low. They may still have an effect. I would like to audit the calculations that are done identifying the dosing.
1 Like
Very interesting. Food for thought. My one concern is I don’t have a full understanding of what the downsides are of high dose melatonin supplementation, the research is in its infancy. Those trials sound interesting (your next post), though I don’t have much time left in my life to wait for long trial results - it’s different for you, you are young.
1 Like
As far as I can tell no-one has managed to kill themselves with an overdose of melatonin. People have tried. There are individual case reports of people trying grams of melatonin to handle cancer. However, I think the system may be resistant to giving ethics approval (IRB/REC) to really high doses.
Hence you have the biohacking option. I feel reasonably comfortable with my own situation simply because I do weekly blood draws and so I have records going back some time. My first concern is not to do any harm.
3 Likes
The only potential concern is Long-term use of melatonin supplements to support sleep may have negative health effects. Unpublished abstract from Nov 2025. However it’s a longitudinal study and RCTs did not find risks:
- Melatonin supplementation improves N-terminal pro-B-type natriuretic peptide levels and quality of life in patients with heart failure with reduced ejection fraction: Results from MeHR trial, a randomized clinical trial 2022
- Melatonin Supplementation and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Trials 2026: “Melatonin was associated with improved LVEF change, particularly in coronary artery bypass grafting settings, but benefit was not consistently demonstrated across final LVEF, troponin, or infarct size outcomes.”
1 Like
Partial answer? => Melatonin as a radioprotectant against mitochondrial damage 2026
Radiation exposure induced mitochondrial damage in TIG-3 cells as evidenced by cytosolic mtDNA leakage, Δψm depolarization, and accelerated cellular senescence. Melatonin and mitoEbselen-2 protected against both irradiation-induced and H2O2-induced mitochondrial damage, suggesting that these agents act as ROS scavengers. Melatonin also maintained Δψm after irradiation and inhibited cellular senescence. However, prolonged mitoEbselen-2 treatment indicated potential cytotoxicity as shown by Δψm loss. Melatonin mitigated the release of exosome mtDNA into the plasma of mice, as well as radiation-induced damage to blood cells and testicular tissue.
2 Likes
Who has done research into SSAO inhibition?
Australian biotech company Syntara has a unique drug for Parkinson’s (SNT-4728) going into phase 2 clinical trials soon
03095814.pdf (1.4 MB)
How does PXS-4728 work in neuro inflammation?
SNT-4728 is a very potent compound that inhibits two key enzymes associated with neuroinflammation:
- Semicarbazide-Sensitive Amine Oxidase (SSAO)
SSAO produces reactive oxygen species (hydrogen peroxide and aldehydes) in the vasculature and an adhesion protein attracting leukocytes (white blood cells) all of which promote inflammation- Monoamine Oxidase-B (MAO-B) MAO-B is an amine oxidase producing reactive oxygen species (hydrogen peroxide and aldehydes) in mitochondria of many cells including microglia and neurons present in the brain.
SNT-4728 has already been the subject of an extensive development program, conducted following a 2015 deal with Boehringer Ingelheim (BI). The asset was shown to be efficacious in pre-clinical work in Nonalcoholic Steatohepatitis (NASH) and subsequently for diabetic retinopathy (DR). However, the program was discontinued by BI in September 2020 primarily because of an off-target effect on an additional inflammatory enzyme in the brain, MAO-B (monoamine oxidase B).
It was identification of this effect, and the significant body of research work underpinning SNT-4728, which has sparked the quest to explore its potential in brain diseases.
Source: Neuroinflammation – Syntara
They just did a webinar about it today that I saw, but it hasn’t been reuploaded yet. The above PDF file is what they used for the webinar but they also had Q&A.
1 Like
I am not sure this answers the question
1 Like
Apparently, the idea is to induce autophagy elimination of alpha-syn through an mTOR inhibitor that works only in the brain. As they claim the downside of rapamycin is that it works in the whole body which is undesirable because it lowers immunity - hmm. I mean at what dose? They don’t say rapamycin is no good because it doesn’t cross the BBB, rather it’s because they don’t want rapamycin working in the rest of the body. Honestly I find that a bit strange - we know in other contexts that rapamycin does have effects on the brain, and if the dose is not too crazy it shouldn’t affect immunity too severely, so why not just use rapamycin? Poke @adssx - your thoughts? In any case does anyone know which specific mTOR inhibitors they are working with? Because mTOR modulators in the brain can have effects not just for PD but AD and dementias in general.
Montara targets Parkinson’s with brain-only drug approach
1 Like
But it doesn’t cross the BBB: Immune cells in the blood drive cognitive ageing — blocking them improves memory - #5 by adssx
Montara has an asset for epilepsy that is MTX-E1 = MT1110 + everolimus: Montara Therapeutics Announces Development Candidate for First BrainOnly™-Enabled Program in TSC-Related Epilepsy and Appoints Chief Business Officer - Montara Therapeutics
Could be the same one?
Yes, I suspect could be the one. That said, I don’t think that a brain mTOR modulator by itself will resolve PD. It might be helpful in the early stage before much destruction of substantia nigra cells has taken place.
1 Like
HER-096 is one of the more interesting Parkinson’s disease drug candidates currently in development because it is trying to do something very different from standard dopamine replacement therapies.
What is HER-096?
HER-096 is a small peptide-like molecule (a peptidomimetic) developed by Herantis Pharma. It was designed from a naturally occurring neuroprotective protein called Cerebral Dopamine Neurotrophic Factor (CDNF). CDNF has shown strong neuroprotective effects in animal models of neurodegeneration, but the full protein is difficult to deliver as a practical drug. HER-096 is essentially a smaller, more drug-like version designed to retain CDNF’s beneficial properties while being easier to administer.
Unlike levodopa, which mainly treats symptoms, HER-096 is being developed as a disease-modifying therapy, meaning the goal is to slow or halt degeneration of dopamine neurons themselves.
Why is it unusual?
Most neurotrophic factors have a major problem:
They do not cross the blood-brain barrier.
They often require direct brain infusion.
Clinical development becomes expensive and invasive.
HER-096 was specifically engineered to:
Survive degradation in the bloodstream.
Cross the blood-brain barrier.
Reach the cerebrospinal fluid after a simple subcutaneous injection.
Remain in the brain longer than in plasma.
That combination is relatively rare and is a major reason the compound has attracted attention.
Mechanism of action
Current evidence suggests HER-096 acts through several pathways simultaneously:
- Reduces ER stress
A major feature of many neurodegenerative diseases is accumulation of misfolded proteins that overwhelm the endoplasmic reticulum (ER).
HER-096 appears to regulate the unfolded protein response (UPR), helping cells cope with protein-folding stress.
- Protects dopamine neurons
In Parkinson’s disease, neurons in the substantia nigra progressively die.
HER-096 promoted survival of dopaminergic neurons in laboratory and animal studies.
- Reduces alpha-synuclein pathology
Alpha-synuclein aggregation is one of the hallmark pathological features of Parkinson’s disease.
Researchers reported reductions in alpha-synuclein aggregates after HER-096 treatment.
- Reduces neuroinflammation
Animal studies showed reductions in markers of neuroinflammation in the substantia nigra.
Animal study results
In aged mouse models of synucleinopathy:
Dopamine neuron loss was reduced.
Alpha-synuclein aggregates were reduced.
Neuroinflammation decreased.
UPR signaling was normalized.
Brain exposure was achieved after subcutaneous dosing.
These findings are encouraging because they hit multiple aspects of Parkinson’s pathology rather than just dopamine production.
Human clinical trials
Phase 1
Healthy volunteer studies demonstrated:
Acceptable safety.
Acceptable tolerability.
Predictable pharmacokinetics.
Subcutaneous administration feasibility.
Phase 1b Parkinson’s trial
The most recent data showed:
Both 200 mg and 300 mg doses were generally safe and well tolerated.
Blood-brain barrier penetration was confirmed in Parkinson’s patients.
Pharmacokinetics matched expectations from earlier studies.
300 mg twice-weekly dosing was selected as suitable for Phase 2.
This is an important milestone because many neuroprotective compounds fail simply because they cannot get into the brain in meaningful amounts.
How advanced is it?
As of the latest public updates:
Phase 1 studies have been completed.
Phase 1b in Parkinson’s patients met its primary and secondary endpoints.
The program is preparing for Phase 2 efficacy testing.
The critical question now is whether the biological effects seen in animals translate into measurable slowing of disease progression in humans.
Why longevity and neurodegeneration researchers might find it interesting
Looking at it through the lens of aging biology rather than just Parkinson’s:
HER-096 appears to influence several mechanisms that show up repeatedly in aging tissues:
Proteostasis dysfunction
ER stress
Protein aggregation
Chronic inflammation
Neuronal survival signaling
Those are not Parkinson-specific phenomena. They are implicated in multiple age-related neurodegenerative diseases.
That does not mean HER-096 is an anti-aging drug, but it is one of the few clinical candidates attempting to directly improve cellular stress-response systems rather than merely replace neurotransmitters.
Biggest reasons for optimism
Crosses the blood-brain barrier.
Simple subcutaneous injection.
Multi-mechanistic action.
Strong preclinical package.
Human BBB penetration already demonstrated.
Good safety profile so far.
Biggest reasons for caution
Nearly every Parkinson’s disease-modifying therapy has looked good in animals.
Parkinson’s drug development has a long history of Phase 2 and Phase 3 failures.
We still do not know whether HER-096 produces meaningful clinical slowing of disease progression.
Current evidence supports biological activity, not efficacy.
From a scientific perspective, the most impressive aspect of HER-096 is not the Parkinson’s indication itself. It is the fact that researchers appear to have created a brain-penetrant CDNF mimetic that can be given by simple injection while retaining neuroprotective activity. If the Phase 2 results are positive, that platform could become relevant far beyond Parkinson’s disease.